Phase 1/2Terminated
Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Pediatric Subjects
- Sponsor
- Incyte Corporation (Industry)
- Enrollment
- 2 enrolled
- Conditions
- Acute Graft-versus-host Disease
- Interventions
- Itacitinib; Corticosteroids
- Ages
- children, adults
- Registry
- NCT03721965, EUCTR2018-002253-30
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate itacitinib in combination with corticosteroids for the treatment of Grades II to IV acute graft-versus-host disease (aGVHD) in steroid-naive pediatric participants.
Primary outcomes
- Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
- Phase 1: Cmax of Itacitinib When Administered With Corticosteroids
- Phase 1: Cmin of Itacitinib When Administered With Corticosteroids
- Phase 1: Tmax of Itacitinib When Administered With Corticosteroids
History
Last registry update
Results first posted
Primary completion
Started
Registered